BioNTech says its experimental cancer drug gotistobart has significantly extended survival in patients with a difficult-to-treat form of lung cancer. The company reported the findings from the PRESERVE-003 Phase 3 trial on Monday. The study examined patients with metastatic squamous non-small cell lung cancer, or NSCLC, whose disease progressed after earlier immunotherapy and chemotherapy. According… Continue reading Gotistobart Lung Cancer: Trial Shows Survival Benefit
Gotistobart Lung Cancer: Trial Shows Survival Benefit